374119-33-2Relevant articles and documents
N-Arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B
Greenspan, Paul D.,Clark, Kirk L.,Cowen, Scott D.,McQuire, Leslie W.,Tommasi, Ruben A.,Farley, David L.,Quadros, Elizabeth,Coppa, David E.,Du, Zengming,Fang, Zheng,Zhou, Huanghai,Doughty, John,Toscano, Karen T.,Wigg, Andrew M.,Zhou, Siyuan
, p. 4121 - 4124 (2003)
To improve the pharmacokinetics of a previously reported series of dipeptidyl nitrile cathepsin B inhibitors, the P2-P3 amide group was replaced with an arylamine. Further optimization of this template resulted in highly potent and s
SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
-
Page/Page column 247, (2008/06/13)
The invention relates to CGRP antagonists of general formula (I), in which A, X, D, E, G, M, Q and R1 to R3 are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts having inorganic or organic acids, to medicaments containing these compounds, to their use, and to methods for the production thereof.